EUVIMEDEUVIMED entdecken
Crossref

Self-Assembled Peptide PROTAC Prodrugs Targeting FOXM1 for Cancer Therapy

Huajie Zeng, Zhiguo Fang, Yinghua Feng, Tong Su, Weibing Miao, Zihua Wang iD

Molecular Pharmaceutics · 02.06.2025 · 22 (6) · 3286-3296

DOI: 10.1021/acs.molpharmaceut.5c00219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 14.05.2025. Verfasst von Huajie Zeng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, …. Hauptthemen laut MEDLINE: Forkhead Box Protein M1, Prodrugs, Peptides, Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Natural Science Foundation of Fujian Province, National Natural Science Foundation of China, Joint Funds for the Innovation of Science and Technology Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis-targeting chimeras (PROTACs) represent a promising strategy for addressing ″undruggable″ proteins in cancer therapy. However, challenges such as poor bioavailability, limited cellular permeability, and inadequate targeting hinder their effectiveness. Herein, we present a novel PROTAC prodrug, NFTP, designed for FOXM1 degradation, which leverages self-assembled peptides functionalized with an integrin α-6 ligand to enhance tumor targeting and proteolysis in vivo. NFTP effectively penetrates tumor cells, induces FOXM1 degradation, inhibits cancer cell survival and migration, and promotes apoptosis in vitro. In a 4T1 mouse xenograft model, NFTP demonstrated efficient FOXM1-targeted degradation, significant tumor growth inhibition, and low systemic toxicity. This self-assembling FOXM1 PROTAC platform demonstrates enhanced tumor-targeting precision and superior therapeutic performance in vivo, representing a promising paradigm shift in targeted cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Forkhead Box Protein M1ProdrugsPeptidesNeoplasmsAntineoplastic AgentsAnimalsMiceHumansCell Line, TumorXenograft Model Antitumor AssaysProteolysisApoptosisFemaleMice, Inbred BALB CCell MovementCell Survival

Stichwörter der Autor:innen

FOXM1PROTACcancer therapyself-assembled peptide

Substanzen

Forkhead Box Protein M1ProdrugsPeptidesFOXM1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350122, China.
  • CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.
  • Department of Epidemiology, School of Public Health, Shanxi Medical University, Taiyuan 030001, China.
  • Department of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350001, China.

ORCID-Profile: Zihua Wang

Förderung

  • Natural Science Foundation of Fujian Province
  • National Natural Science Foundation of China
  • Joint Funds for the Innovation of Science and Technology Fujian Province

Zitieren

APA

Zeng, H., Fang, Z., Feng, Y., Su, T., Miao, W., & Wang, Z. (2025). Self-Assembled Peptide PROTAC Prodrugs Targeting FOXM1 for Cancer Therapy. Molecular Pharmaceutics, 22(6), 3286-3296. https://doi.org/10.1021/acs.molpharmaceut.5c00219

Vancouver

Zeng H, Fang Z, Feng Y, Su T, Miao W, Wang Z. Self-Assembled Peptide PROTAC Prodrugs Targeting FOXM1 for Cancer Therapy. Molecular Pharmaceutics. 2025;22(6):3286-3296. doi:10.1021/acs.molpharmaceut.5c00219

BibTeX
@article{Zeng2025,
  author = {Zeng, Huajie and Fang, Zhiguo and Feng, Yinghua and Su, Tong and Miao, Weibing and Wang, Zihua},
  title = {Self-Assembled Peptide PROTAC Prodrugs Targeting FOXM1 for Cancer Therapy},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  volume = {22},
  number = {6},
  pages = {3286--3296},
  doi = {10.1021/acs.molpharmaceut.5c00219}
}
Kostenlos starten →